Cell Therapy Technologies Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032
Report ID: GMI5541
Download Free PDF
Authors:
Mariam Faizullabhoy ,
Cell Therapy Technologies Market Size
The global cell therapy technologies market generated notable revenue in 2024 and is expected to grow at a decent CAGR during 2025-2034, due to the rising prevalence of chronic diseases, cancer, and genetic disorders, which can be treated using innovative cell-based treatments. As per WHO, in 2022, around 20 million new cancer diagnoses occurred, along with 9.7 million cancer-related deaths. The market growth is also driven by advancements in cellular therapies for a wide range of chronic diseases, particularly in the field of immunotherapy and regenerative medicine. Cell therapies, which involve the use of living cells to treat various conditions, offer promising solutions for treating them. The market’s expansion is attributed to increased research in cell-based therapies, evolving healthcare needs, and the increasing prevalence of diseases that can benefit from these treatments.
Moreover, the demand for cell-based therapies is increasing due to advancements in manufacturing technologies, which make cell therapies more accessible and affordable. However, the market faces challenges related to the high cost of cell-based therapies and the complexity of manufacturing these therapies.
Cell Therapy Technologies Market Trends
The cell therapy technologies industry is undergoing significant changes, with several trends shaping its future growth. One of the key trends is the increasing adoption of personalized cell therapies. This approach tailors treatments to individual patients’ genetic profiles, offering more effective and targeted therapeutic options. Personalized treatments are particularly prominent in the field of oncology, where cellular therapies like CAR-T cell therapy are showing promise in targeting specific cancer cells.
Moreover, the development of allogeneic cell therapies, where cells are derived from healthy donors, is gaining traction as it offers the potential for off-the-shelf treatments. This contrasts with autologous therapies, which involve using a patient’s own cells. Allogeneic therapies are expected to be more cost-effective and widely accessible, which could expand their application in clinical settings. Another trend influencing the market is the continued investment in automation and artificial intelligence (AI) to streamline cell therapy manufacturing. These technologies aim to address the complexities and cost barriers associated with large-scale production of cell therapies.
Cell Therapy Technologies Market Analysis
The T-cell segment in the cell therapy technologies market is expected to witness significant through 2034 due to the increasing number of approved therapies in oncology and immunotherapy. T-cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, have revolutionized cancer treatment. CAR-T therapy has shown substantial efficacy in treating various types of blood cancers, including leukemia and lymphoma. These therapies are designed to genetically modify a patient's T-cells to better recognize and attack cancer cells.
As of 2023, several CAR-T therapies have gained approval from regulatory bodies like the U.S. Food and Drug Administration (FDA), including Kymriah, Yescarta, and Tecartus, among others. This success has spurred ongoing research into expanding T-cell therapies for solid tumors, autoimmune diseases, and other conditions. The growing body of evidence supporting the effectiveness of T-cell-based therapies, combined with increasing cancer incidences globally, is set to drive demand for these technologies. However, challenges such as the high cost and the potential for severe side effects limit the broader adoption of these therapies.
Based on end use, the Cell banks and research institutes segment in the cell therapy technologies market is expected to hold the largest share by 2034. These organizations provide the necessary infrastructure and expertise for the development, storage, and distribution of cell-based therapies. Cell banks are responsible for the production and maintenance of high-quality cell lines, which are essential for research, clinical trials, and the commercial production of cell therapies. Research institutes, on the other hand, help in advancing scientific knowledge in cell biology and developing new therapeutic applications for cell therapies. These institutions work closely with biotech and pharmaceutical companies to drive innovation in cellular medicine, including stem cell research, tissue engineering, and gene editing technologies like CRISPR. The increasing investments in research activities, both public and private, are expected to further fuel the market. Collaboration between pharmaceutical companies, research institutes, and healthcare providers will likely accelerate the development of new and more effective cell therapies, providing growth opportunities in the coming years.
North America cell therapy technologies market is expected to maintain its CAGR growth through 2034. The region’s dominance is driven by several factors, including a well-established healthcare infrastructure, advanced research & development capabilities, and a high prevalence of diseases that are treatable with cell therapies. The United States is the largest market for cell therapies, due to its robust pharmaceutical industry and regulatory support for the commercialization of novel therapies. The approval of CAR-T therapies, as well as the growing number of clinical trials and FDA-approved cell therapies, has positioned North America at the forefront of innovation in cell therapy technologies. Moreover, the region benefits from a strong pipeline of cell-based therapies, backed by substantial funding and investment in biotech companies, which are key drivers of market growth. The U.S. government’s initiatives to support regenerative medicine and immunotherapy research, along with favorable reimbursement policies, have further contributed to North America's dominant position in the market.
Cell Therapy Technologies Market Share
The cell therapy technologies market is highly competitive, with several key players driving innovation in this field. Leading companies in this market include:
Companies such as Novartis, Gilead Sciences, Bristol Myers Squibb, and Merck & Co., also have made significant investments in the development of CAR-T and other cell-based therapies. These companies are actively involved in expanding their cell therapy portfolios, improving manufacturing processes, and exploring new therapeutic indications.
In addition, emerging biotech companies like Kite Pharma, Autolus Therapeutics, and Celyad Oncology are working on cutting-edge technologies that aim to improve the efficacy and safety profiles of cell therapies. The cell therapy technologies market is also witnessing strategic partnerships and collaborations between pharmaceutical companies, academic institutions, and research organizations, which are aimed at accelerating the development and commercialization of cell therapies.
Cell Therapy Technologies Industry News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →